Abstract:
The use of GapC plasmin binding proteins from Streptococcus dysgalactiae (S. dysgalactiae) , Streptococcus agalactiae (S. agalactiae) , Streptococcus uberis (S. uberis) , Streptococcus parauberis (S. parauberis) , and Streptococcus iniae (S. iniae) in combination with CAMP factors is described, to prevent or treat bacterial infections in general, and mastitis in particular.
Abstract:
The use of GapC plasmin binding proteins from Streptococcus dysgalactiae (S. dysgalactiae) , Streptococcus agalactiae (S. agalactiae) , Streptococcus uberis (S. uberis) , Streptococcus parauberis (S. parauberis) , and Streptococcus iniae (S. iniae) in combination with CAMP factors is described, to prevent or treat bacterial infections in general, and mastitis in particular.
Abstract:
The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S.iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.
Abstract:
The Mig protein gene of Streptococcus dysgalactiae, and the corresponding amino acid sequence, is described, as is the use of the Mig protein in vaccine compositions to prevent and treat bacterial infections in general, and mastitis in particular.
Abstract:
The Mig protein gene of Streptococcus dysgalactiae, and the corresponding amino acid sequence, is described, as is the use of the Mig protein in vaccine compositions to prevent and treat bacterial infections in general, and mastitis in particular.
Abstract:
The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S.iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.